Madrigal Pharmaceuticals, Inc. (MDGL) Guidance & Earnings Results
On 2026-02-19 Madrigal Pharmaceuticals, Inc. raised guidance: "Expects another year of robust net sales…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDGLMadrigal Pharmaceuticals, Inc.Follow MDGL — free
—
Price chart with a free account
- Market cap
- 10.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 19 Feb 26 | Raised | Expects another year of robust net sales growth |
| 4 Nov 25 | Raised | Rezdiffra sales annualizing above $1B; positive outlook for 2026 · full year |
Madrigal Pharmaceuticals, Inc. — questions
- What guidance did Madrigal Pharmaceuticals, Inc. give?
- On 2026-02-19: "Expects another year of robust net sales growth"
- When does Madrigal Pharmaceuticals, Inc. report earnings?
- Madrigal Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-03.
Every figure on this page comes from Madrigal Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.